Gefitinib, an epidermal growth factor receptor inhibitor and licensed under the trade name Iressa, has been used in the clinic since 2009 to treat patients with non-small cell lung cancer (Dhillon, 2015). This evidence concerns the gene EGFR and non-small cell lung carcinoma.